The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | The role of melflufen in the myeloma treatment landscape
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the role of melflufen in the myeloma treatment landscape, particularly for patients who have become refractory to immunotherapies. Melflufen shows good efficacy and is well-tolerated, even in elderly patients who are difficult to treat. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Sanofi, GSK, Janssen, BMS-Celgene, Takeda and Karyopharm.
